Hanmi Science Co., Ltd.
008930.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.72T
Close$
$38121.14
16.1% downside
Current Fair Value
16.1% downsideOvervalued by 16.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.72 Trillion |
|---|---|
| Enterprise Value | $3.84 Trillion |
| Dividend Yield | $400.00 (0.55%) |
| Earnings per Share | $1748.09 |
| Beta | 0.45 |
| Outstanding Shares | 68,393,000 |
Return
| Return on Equity | 14.22% |
|---|---|
| Return on Assets | 9.85% |
| Return on Invested Capital | 7.84% |
Valuation & Multiples
| P/E Ratio | 25.08 |
|---|---|
| PEG | 48.41 |
| Price to Sales | 2.21 |
| Price to Book Ratio | 2.93 |
| Enterprise Value to Revenue | 2.72 |
| Enterprise Value to EBIT | 43.84 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.06 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Hanmi Science Co., Ltd.
489 employees
CEO: Jong-Hoon Lim Hanmi Science Co., Ltd. operates through its subsidiaries to produce and distribute pharmaceutical products both within South Korea and internationally. The company's research and development initiatives primarily target treatments for d...